$AHPA News
Last published 3y ago
- 3y agoAHPALGNDOABIOmniAb Reports Third Quarter 2022 Financial Results and Business HighlightsBusiness WireOmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated
- 4y agoAHPALGNDOABIOmniAb Announces Completion of Spin-Off and Business CombinationBusiness WireLeading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the
- 4y agoAHPALGNDLigand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBusiness WireFirst FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals
- 4y agoAHPALGNDOmniAb Business Combination Approved by APAC ShareholdersBusiness WireAPAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022 Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022 Ligand Pharmaceuticals
- 4y agoAHPALGNDLigand Announces Record Date and Details for Distribution for OmniAb Spin-OffBusiness WireLigand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders i
- 4y agoAHPAAvista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business CombinationPR NewswireExtraordinary General Meeting of APAC Shareholders to Vote on Proposed Business Combination with OmniAb to be Held on October 24, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Avista Public Acquisition Corp. II (NASDAQ:AHPA) ("APAC") announced today th
- 4y agoAHPALGNDLigand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBusiness WireFirst European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that t
- 4y agoAHPALGNDLigand Reports Second Quarter 2022 Financial ResultsBusiness WireRaises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating for
- 4y agoAHPALGNDLigand Reports First Quarter 2022 Financial ResultsBusiness WireConference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand managem
- 4y agoAHPAHBPPLANYMoore Kuehn Encourages PLAN, HBP, Y, And AHPA Investors To Contact Law FirmPR NewswireNEW YORK, March 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sh
- 4y agoAHPALGNDLigand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. IIBusiness WireTransaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Ligand's shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporate